Skip to main content

Table 4 Factors associated with rebleeding

From: Antiviral therapy reduces rebleeding rate in patients with hepatitis B-related cirrhosis with acute variceal bleeding after endotherapy

Variable

Univariate analysis OR (95%CI)

p

Multivariate analysis OR (95%CI)

p

Age (yr)

1.011 (1.000–1.023)

0.059

  

Gender

1.021 (0.781–1.336)

0.878

  

Antiviral therapy

0.576 (0.428–0.777)

<0.001

0.563 (0.389–0.817)

0.002

Diabetes

1.810 (1.368–2.395)

<0.001

1.893 (1.347–2.662)

<0.001

Alcohol consumption

1.179 (0.595–2.336)

0.637

  

Ascites

2.053 (1.513–2.787)

<0.001

1.820 (1.253–2.642)

0.002

WBC (×109/L)

1.003 (0.969–1.039)

0.858

  

LY%

0.986 (0.974–0.998)

0.026

  

PLT (×109/L)

1.002 (1.000–1.004)

0.122

  

HGB (g/l)

0.992 (0.987–0.997)

0.001

0.994 (0.988–0.999)

0.032

ALT (U/L)

1.001 (0.999–1.004)

0.241

  

AST (U/L)

1.003 (1.001–1.006)

0.012

  

GGT (U/L)

1.011 (1.006–1.015)

<0.001

1.011 (1.006–1.016)

<0.001

TBIL (μmol/l)

1.004 (0.999–1.008)

0.124

  

CHE (U/L)

1.000 (1.000–1.000)

0.014

  

HBeAg (positive)

0.934 (0.696–1.252)

0.646

  

HBV-DNA (positive)

0.948 (0.685–1.313)

0.750

  

AFP (ng/ml)

1.003 (1.001–1.005)

0.007

  

MELD score

1.010 (0.984–1.036)

0.474

  

CTP class

1.492 (1.242–1.792)

<0.001

  
  1. WBC white blood cell, LY% percentage of lymphocytes, PLT Platelet, ALT alanine aminotransferase, GGT gamma-glutamyl transpeptidase, CHE cholinesterase, AFP alpha fetoprotein, HBeAg hepatitis B virus e antigen, HBV-DNA hepatitis b virus deoxyribonucleic acid, CTP class Child-Turcotte-Pugh class, MELD model for end-stage liver disease